View Post

New Pharma Trials Making Big Gains in Fight Against Triple-Negative Breast Cancer (TNBC)

In Clinical Studies News by Barbara Jacoby

Source: USA News Group From: prnewswire.com Triple-negative Breast Cancer (TNBC) is a highly aggressive subtype that accounts for 15-20% of breast cancer cases and 25% of all breast cancer deaths. Unlike other breast cancers, treatments for TNBC involving hormone therapy and drugs that target HER2 protein are not helpful. With a dire need for new forms of treatment, there’s plenty of optimism …

View Post

New Research Presented at Virtual ASTRO Meeting Supports Xoft System for Treatment of Early-Stage Breast Cancer and Gynecological Cancers

In Clinical Studies News by Barbara Jacoby

From: globenewswire.com iCAD Showcasing Expanded Xoft Platform Including Single-Fraction IORT Solution for Brain and Early-Stage Breast Cancer Tumors iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will showcase the expanded platform for the Xoft® Axxent® Electronic Brachytherapy (eBx®) System® at the American Society for Radiation Oncology (ASTRO) Virtual …

View Post

Hypofractionated RT: A Potential New Standard Treatment for Certain Breast Cancers

In Clinical Studies News by Barbara Jacoby

By: Leah Lawrence From: cancertherapyadvisor.com A new study suggested that moderately hypofractionated whole-breast irradiation was safe and effective, and could be recommended as a standard therapy for breast-only radiotherapy in women who undergo breast-conserving surgery for node-negative early breast cancer. The study randomly assigned 1854 women to receive radiotherapy at either 50 Gy in 25 fractions or the hypofractionated rate …

View Post

The Future of Breast Cancer Treatment: Destroying Tumors with a Laser

In In The News by Barbara Jacoby

By: Liz Dowling Breast cancer patients have long been in need of reliable therapeutic options that reduce pain and the risk of disfigurement. At the forthcoming MedTech conference of the Advanced Medical Technology Association (AdvaMed, Washington, DC), laser therapy specialist Novian Health Inc (Chicago) will showcase a novel technology for the ablation of early-stage breast tumors. The company’s CE-marked system …

View Post

Trial finds benefit of immunotherapy-chemotherapy combination in early-stage triple-negative breast cancer

In Clinical Studies News by Barbara Jacoby

By: Dana Farber Cancer Institute From: medicalxpress.com Adding an immunotherapy agent to a three-drug chemotherapy regimen can improve the likelihood that early-stage triple-negative breast cancer will recede to undetectable levels, data from a clinical trial led by Dana-Farber/Brigham and Women’s Cancer Center suggests. The results of the trial, dubbed the IMpassion031 study, will be presented at the 2020 Congress of …

View Post

Oncogeriatric Approach Linked to More Treatment, Improved Outcomes

In Clinical Studies News by Barbara Jacoby

By: Christina Bennett, MS From: cancertherapyadvisor.com Older patients with early-stage breast cancer who were treated using an oncogeriatric approach were more likely to receive adjuvant treatments and had improved clinical outcomes compared with patients who were treated with the standard of care, found a retrospective observational study published in Breast Cancer Research and Treatment. The study included patients 70 years …

View Post

Survival Consistent for Women With Early-Stage Breast Cancer Despite Surgery Delays

In In The News by Barbara Jacoby

By: Maggie L. Shaw From: ajmc.com Delays in surgery to treat early-stage breast cancer and receiving neoadjuvant endocrine therapy did not decrease survival odds among female patients, authors report in the Journal of the American College of Surgeons. Overall delays in surgical procedures to treat early-stage breast cancer, particularly estrogen-sensitive early-stage disease, as well as receiving neoadjuvant endocrine therapy (NET) …

View Post

Mortality Among Men With Breast Cancer Decreases With Adjuvant Chemotherapy

In Clinical Studies News by Barbara Jacoby

By: Maggie L. Shaw From: ajmc.com Less than 1% of all breast cancers occur in men, making this a rare disease among that patient population, and most treatment guidelines are based on outcomes and survival rates seen in women with the disease. A recent study published in Cancer investigated the effects of adjuvant chemotherapy for early-stage breast cancer solely among …

View Post

G-CSF Cuts Febrile Neutropenia Rates in Early Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Liam Davenport From: medscape.com Women with early-stage breast cancer had a significantly lower rate of febrile neutropenia when given granulocyte-colony stimulating factors (G-CSF) alongside their chemotherapy rather than the antibiotic ciprofloxacin, indicate new data from a randomized trial. The research was presented at the 2020 annual meeting of the American Society of Clinical Oncology, held virtually because of the …

View Post

Neratinib Shows Strong Benefit in Early-Stage, Metastatic HER2+ Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Caroline Seymour From: onclive.com Neratinib’s (Nerlynx) greatest impact is in the early-stage setting in women with high-risk, HER2-positive breast cancer, said Joyce A. O’Shaughnessy, MD, who added that the agent can also be of benefit to patients with metastatic disease. “The ExteNET data [provide compelling evidence] that giving 1 year of neratinib along with endocrine therapy [in the extended …